Compare International Business Machines Corp (IBM) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
International Business Machines Corp vs Repligen Corporation Common Stock — how do they compare? International Business Machines Corp trades at $228.5 (market cap $217.43B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: International Business Machines Corp is far larger — about 19.5× Repligen Corporation Common Stock's market cap, and International Business Machines Corp pays a 2.93% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold International Business Machines Corp for 89 Days and Repligen Corporation Common Stock for 0 Days on average.
| IBM | RGEN | |
|---|---|---|
Market Cap | $217.43B | $11.14B |
Volume | 5,119,486 | 1,259,263 |
Sector | Technology | Health |
52-Week High | $329.23 | $194.57 |
52-Week Low | $205.77 | $102.87 |
Typical Hold Time | 89 Days | 0 Days |
Enterprise Value | $274.57B | $11.02B |
Dividend Yield | 2.93% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IBM trades at $227.88, up 0.38% with a bearish technical signal despite recent positive momentum. The company shows strong fundamentals with 2025 revenue of $67.54B and net income of $10.59B, representing a 15.52% margin. Recent earnings beat expectations in two of the last three quarters, while Q3 2026 results are pending. Analyst consensus is mixed with 47% buy ratings and a $255.50 price target, suggesting 12% upside potential from current levels.
IBM presents a balanced opportunity with solid profitability and AI consulting growth offset by cyclical mainframe weakness and negative cash flow trends. The stock's current valuation at 20.5x P/E appears reasonable given the company's pivot to high-margin hybrid cloud and AI services. Key risks include execution challenges in the AI transition and competitive pressures in the consulting space.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About International Business Machines Corp
International Business Machines Corporation (IBM) provides computer solutions. The Company offers application, technology consulting and support, process design and operations, cloud, digital workplace, and network services, as well as business resiliency, strategy, and design solutions. IBM serves clients worldwide.
Read more on IBM →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
